BPC-157 is a synthetic peptide derived from proteins naturally found in your stomach's protective lining
10.1016/j.bbi.2012.04.001 149
document HbA1c target and achieved level Symptomatic pain management: pregabalin, gabapentin, duloxetine (FDA-approved for DPN), TCAs Foot care: preventive podiatry, custom diabetic footwear (HCPCS A5500A5513), monofilament testing Cardiovascular autonomic: fludrocortisone, midodrine for orthostatic hypotension
It is not intended for human or animal consumption, therapeutic use, or diagnostic application.
Common Side Effects When side effects occurred, they were typically mild, transient, and similar in frequency to placebo groups: Reported Adverse Effects Most Common (occurring in small percentage of participants): Mild to moderate headaches (most frequently reported, often resolving with continued use) Injection site reactions (minor redness, swelling, or irritation at injection site) Gastrointestinal effects (particularly at higher oral doses: mild nausea, diarrhea, flatulence) Fatigue (reported occasionally during initial adaptation period) Rare Events: One case of chest tightness was deemed possibly related to treatment in safety trials
En modelos murinos de enfermedad inflamatoria intestinal, el tratamiento oral con BPC-157 se asocio con reduccion de la inflamacion colonica, cicatrizacion mucosa acelerada y mejora en las puntuaciones de actividad de la enfermedad
